Viking Therapeutics (VKTX) reports Q3 2026 results today after the bell, with a 4:30 p.m. ET conference call to follow. Analysts expect a loss and zero revenue, the normal reality for a clinical-stage biotech burning cash across multiple active programs. Shares closed Tuesday near their 52-week low of $23.82, down roughly 41% over the past month and 31% year-to-date.
That selloff is the acquisition angle worth examining today.
What Viking Actually Has
VK2735 is now running in four concurrent trials. The VANQUISH-1 and VANQUISH-2 subcutaneous Phase 3 programs are fully enrolled; VANQUISH-2 alone includes approximately 1,000 adults with type 2 diabetes and obesity. On October 14, Viking initiated the SUNRISE Phase 3 program for the oral tablet formulation, with SUNRISE-1 and SUNRISE-2 each targeting 560 adults across 68 weeks of treatment. A separate maintenance dosing trial, launched October 6, is exploring whether patients can sustain weight loss by transitioning from weekly injections to daily or weekly oral dosing, or to less-frequent injections.
The Phase 2 data underpinning all of this is real. Subcutaneous VK2735 delivered weight reductions up to 14.7% after 13 weekly doses with no plateau observed. More recent maintenance data indicated patients maintained up to 97% of the weight they lost with every-other-week injections and up to 90% with monthly injections, compared with placebo in that study.
Where Lilly Sits
Eli Lilly generated $19.8 billion in Q1 2026 revenue, up 56% year-over-year, with Mounjaro and Zepbound together accounting for about 65% of that total. Mounjaro alone hit $8.7 billion in the quarter. Foundayo (orforglipron), Lilly’s oral GLP-1 pill, was approved by the FDA on April 1, 2026.
With 2026 guidance raised, now sitting between $85 billion and $87 billion, Lilly has the balance sheet to write a very large check. The strategic logic for buying Viking is straightforward: VK2735 is one of the most advanced GLP-1/GIP obesity assets not yet owned by a major pharma company, and acquiring it while VKTX trades near multi-year lows would cost a fraction of what it would have six months ago.
The Complication
Antitrust is the friction point. Lilly already has a dominant position in obesity and diabetes incretins, and adding the field’s top independent pipeline asset to that position would draw scrutiny. Polymarket implied a 38.5% probability of VKTX being acquired before 2027 as of May, with Lilly cited as the most logical buyer, but the antitrust optics complicate the fit for a company already at Lilly’s scale.
That creates a question traders should hold through today’s earnings call: if management signals confidence in SUNRISE enrollment timelines and the maintenance data story, does the stock’s current discount invite a competing bid from a buyer with less market share exposure? Novo Nordisk, Pfizer, or AstraZeneca each carry lighter incretin baggage than Lilly does.
What to Watch on the Call
- Cash position versus the $502 million reported at end of Q2, given rising R&D across VANQUISH and SUNRISE combined enrollment of roughly 5,500+ patients
- Any updated timeline for VANQUISH-1 top-line data, expected around mid-2027
- Management tone on partnership or licensing conversations
The 21-analyst consensus price target sits at $95.05, more than three times the current price. The gap between where the stock trades and where analysts think it belongs is large enough to keep M&A speculation alive regardless of what the Q3 numbers look like tonight.
